T-DXd leads to longer overall survival in HER2-positive metastatic breast cancer pati

[News]

Second-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer, according to updated results from the DESTINY-Breast03 phase III clinical trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

More... (https://www.news-medical.net/news/20221207/T-DXd-leads-to-longer-overall-survival-in-HER2-positive-metastatic-breast-cancer-patients-than-T-DM1.aspx)